Page 272 - வாஷிங்டன் பல்கலைக்கழகம் இல் ஸ்டம்ப் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Wandering cops shuffle departments, abusing citizens
washingtontimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from washingtontimes.com Daily Mail and Mail on Sunday newspapers.
Wandering cops shuffle departments, abusing citizens
570news.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 570news.com Daily Mail and Mail on Sunday newspapers.
Providence Health Sonoma County urologic surgeon wins Forty under 40 award
northbaybusinessjournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from northbaybusinessjournal.com Daily Mail and Mail on Sunday newspapers.
Q BioMed Updates Shareholders
Technology partner, Mannin Research, receives new R&D funding for COVID project and Several Milestones Expected in 2021
News provided by
Share this article
Share this article
NEW YORK, April 27, 2021 /PRNewswire/ Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, updates shareholders.
In March 2021,it was announced that our technology partner, Mannin Research Inc. (Mannin), is receiving up to CAD$1.7 million in research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the pre-clinical development of a therapeutic to treat Acute Respiratory Distress Syndrome in COVID-19. This funding adds to approximately $7 million granted in Europe, which together will fund 65-75 percent of every dollar incurred to advance the Acute Respiratory Distress Syndrome therapy for COVID patients as well as a portfolio of therapeutic assets for vascular diseases currently i
Share this article
COLUMBIA, Md., April 27, 2021 /PRNewswire/
Foundation Fighting Blindness, the world s leading organization committed to finding treatments and cures for blinding retinal diseases, announces that it has appointed Claire M. Gelfman, Ph.D. as chief scientific officer. In her new role, Dr. Gelfman will be responsible for leading the overarching scientific strategy for the organization with a focus on research initiatives designed to accelerate new treatments and cures for inherited retinal diseases.
Additionally, Dr. Gelfman will oversee the Foundation s non-clinical research portfolio, including early translational and pre-clinical research programs. She will also serve as the primary scientific contact with the Foundation s Scientific Advisory Board, the Research Oversight Committee, academic institutions, and government science agencies.